The Journal of the American Thyroid Association, Thyroid, has published an editorial ahead of print entitled: Changing the Cancer Diagnosis: The Case of Follicular Variant of Papillary Thyroid Cancer-Primum Non Nocere and NIFTP. Although the full editorial is not currently available to the public, the first page can be viewed on the Journal’s website.
The authors of the editorial are also among the authors of the JAMA article which proposed the reclassification of N-EFVPTC to NIFTP. They are Steven Hodak of NYU Langone; R. Michael Tuttle of Memorial Sloan Kettering Cancer Center; Guy Maytal of Massachusetts General Hospital and Harvard Medical School; Yuri Nikiforov of UPMC Pittsburgh; and Gregory Randolph, Of The Massachusetts Eye and Ear Infirmary, Mass General and Harvard Medical School.
The editorial states that for many thyroid cancer patients, physicians may be violating the important dictum in medicine, “First, do no harm.” This is because recent studies have indicated that thyroid cancer imposes significant financial and emotional burdens on patients which have apparently gone largely unacknowledged until now.
Instead of recognizing these burdens, physicians have traditionally relied upon a policy of “social utilitarianism”, meaning trying to to the most good for the greatest number of patients through the implementation of cookie cutter treatments. Under this philosophy, both high and low risk patients have received almost identical interventions for thyroid cancer.
The editorial appears to make a strong case that pathologists, endocrinologists and surgeons who are involved in the field of thyroid cancer have an ethical obligation to their patients with respect to NIFTP. This means not only an obligation to reduce harm through implementation of the reclassification, but an additional moral imperative to go back and correct past harms by reviewing cases which were classified as N-EFVPTC over the years.